| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Purity: ≥98%
GNF351 (GNF-351) is a novel and potent full aryl hydrocarbon receptor (AHR) antagonist with the potential to be used as new drugs in dermatology. GNF351 competes with a photoaffinity AHR ligand for binding to the AHR with an IC50 of 62 nM. GNF351 is minimal toxicity in mouse or human keratinocytes.
| ln Vitro |
GNF351 (500 nM, 48 hours) treatment of proliferating monolayers of human ex vivo cell cultures considerably lowers the total number of Ki67-positive cells and cell number [1].
|
|---|---|
| Cell Assay |
Cell Proliferation Assay[1]
Cell Types: Human Primary keratin cells Tested Concentrations: 500 nM Incubation Duration: 48 hrs (hours) Experimental Results: Significant percentage of Ki67-positive cells and cell number after 48 hrs (hours) of treatment of proliferating human keratinocyte monolayer cultures reduce. |
| References |
| Molecular Formula |
C24H25N7
|
|---|---|
| Molecular Weight |
411.502203702927
|
| Exact Mass |
411.217
|
| CAS # |
1227634-69-6
|
| PubChem CID |
46216378
|
| Appearance |
Off-white to light yellow solid powder
|
| LogP |
4.1
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
31
|
| Complexity |
586
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
N1(C=NC2=C(N=C(C3C=NC=C(C)C=3)N=C12)NCCC1=CNC2C=CC=CC1=2)C(C)C
|
| InChi Key |
WWERDIHAUJLVQP-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C24H25N7/c1-14(2)31-20(9-8-16-13-27-19-7-5-4-6-18(16)19)28-21-22(25)29-23(30-24(21)31)17-10-15(3)11-26-12-17/h4-7,10-14,27H,8-9H2,1-3H3,(H2,25,29,30)
|
| Chemical Name |
8-(2-(1H-indol-3-yl)ethyl)-9-isopropyl-2-(5-methylpyridin-3-yl)-9H-purin-6-amine
|
| Synonyms |
GNF-351; GNF351 GNF 351.
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 125 mg/mL (~303.77 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (5.05 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (5.05 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4301 mL | 12.1507 mL | 24.3013 mL | |
| 5 mM | 0.4860 mL | 2.4301 mL | 4.8603 mL | |
| 10 mM | 0.2430 mL | 1.2151 mL | 2.4301 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA